Mail

UK markets closed

FTSE 100
7,585.46
+20.54(+0.27%)
FTSE 250
20,372.52
+123.78(+0.61%)
AIM
968.25
+10.25(+1.07%)
GBP/EUR
1.1764
+0.0023(+0.20%)
GBP/USD
1.2631
+0.0025(+0.20%)
BTC-GBP
22,964.43
+54.86(+0.24%)

Urban appeal of city centre homes

Urban living is back in fashion after a brief move away from cities during the pandemic

WuXi Biologics (Cayman) Inc. (2269.HK)

HKSE - HKSE Delayed price. Currency in HKD

Add to watchlist

54.300

+3.650

(+7.21%)

At close: 04:08PM HKT

Currency in HKD

Valuation measures⁴

Market cap (intra-day)	220.03B
Enterprise value	212.11B
Trailing P/E	58.28
Forward P/E	42.55
PEG ratio (5-yr expected)	1.42
Price/sales (ttm)	19.28
Price/book (mrq)	5.86
Enterprise value/revenue	20.61
Enterprise value/EBITDA	46.99

Trading information

Stock price history

Beta (5Y monthly)	1.14
52-week change ³	-55.23%
S&P500 52-week change ³	-1.04%
52-week high ³	148.000
52-week low ³	40.300
50-day moving average ³	57.649
200-day moving average ³	87.216

Share statistics

Avg vol (3-month) ³	29.19M
Avg vol (10-day) ³	18.66M
Shares outstanding ⁵	4.22B
Implied shares outstanding ⁶	N/A
Float ⁸	3.56B
% held by insiders ¹	15.76%
% held by institutions ¹	49.33%
Shares short ⁴	N/A
Short ratio ⁴	N/A
Short % of float ⁴	N/A
Short % of shares outstanding ⁴	N/A
Shares short (prior month ) ⁴	N/A

Dividends & splits

Forward annual dividend rate ⁴	N/A
Forward annual dividend yield ⁴	N/A
Trailing annual dividend rate ³	0.00
Trailing annual dividend yield ³	0.00%
5-year average dividend yield ⁴	N/A
Payout ratio ⁴	0.00%
Dividend date ³	N/A
Ex-dividend date ⁴	N/A
Last split factor ²	3:1
Last split date ³	16 Nov 2020

Financial highlights

Currency in CNY.

Fiscal year

Fiscal year ends	31 Dec 2021
Most-recent quarter (mrq)	31 Dec 2021

Profitability

Profit margin	32.93%
Operating margin (ttm)	30.81%

Management effectiveness

Return on assets (ttm)	5.43%
Return on equity (ttm)	13.09%

Income statement

Revenue (ttm)	10.29B
Revenue per share (ttm)	2.46
Quarterly revenue growth (yoy)	60.40%
Gross profit (ttm)	4.8B
EBITDA	3.62B
Net income avi to common (ttm)	3.39B
Diluted EPS (ttm)	N/A
Quarterly earnings growth (yoy)	62.30%

Balance sheet

Total cash (mrq)	11.13B
Total cash per share (mrq)	2.63
Total debt (mrq)	4.3B
Total debt/equity (mrq)	13.13
Current ratio (mrq)	2.37
Book value per share (mrq)	7.64

Cash flow statement

Operating cash flow (ttm)	3.43B
Levered free cash flow (ttm)	-3.72B